PhD - Impact of intratumoral heterogeneity on treatment resistance and tumor relapse in glioblastoma

Luxembourg Institute of Health
September 18, 2023
Offerd Salary:Negotiation
Working address:N/A
Contract Type:fixed-term contract
Working Time:Full time
Working type:N/A
Ref info:N/A
  • Our Jobs
  • PhD - Impact of intratumoral heterogeneity on treatment resistance and tumor relapse in glioblastoma
  • PhD - Impact of intratumoral heterogeneity on treatment resistance and tumor

    relapse in glioblastoma

    The DNA Repair and Chemoresistance Group (DRC) headed by Dr. Eric Van Dyck at the Department of Cancer Research (DoCR) carries out fundamental and translational research on the molecular mechanisms governing DNA repair, chromatin dynamics and chemoresistance in cancer. Our main research interest resides in the identification & validation of novel strategies to improve cancer treatment, with a particular focus on gliomas. As part of a collaborative Télévie Research Project with the GIGA-Neurosciences (ULiège, Belgium) and the Laboratoire National de Santé (LNS, Luxembourg), the DRC is seeking to recruit a highly motivated PhD student.

    Rue Nicolas-Ernest Barblé 6A, Luxembourg L-1210, Luxembourg

    18/08/2023 10:35:38 PROJECT

    Despite surgery and a combination of radio- and chemotherapy, the outcome for patients with glioblastoma (GBM) remains dismal. Intratumoral heterogeneity manifested by the presence of tumor cells with different properties and levels of resistance to chemoradiation poses a crucial challenge in GBM therapy. We have described a unique gene expression signature that classifies GBM specimens in two major groups displaying profound differences in proliferation as well as DNA repair and cell cycle gene expression (Cancer Res (2019) 79 (6): 1226–1238. https: // Several lines of evidence suggest that our signature should be a useful tool to interrogate intratumoral heterogeneity in GBM. The aim of the project is to better understand how spatial changes in DNA repair and cell cycle expression can be linked to tumor progression and treatment response, and examine the impact of intratumoral heterogeneity on tumor relapse. To reach this goal, an experimental strategy will be developed that combines state-of-the-art multiplexed immunohistochemistry (IHC) and proteomics approaches for the characterization of preclinical animal models and patient biopsies.

    KEY responsibilities
  • Participate in the setting-up and implementation of a collaborative research project
  • Conduct a research project with the aims of submitting a PhD thesis dissertation and obtaining a PhD degree
  • Publish results in scientific journals and/or file patents if applicable
  • Participate in training and international scientific conferences
  • Disseminate results to the scientific community and the public
  • Participate in laboratory activities including seminars and interaction with other team
  • Master's degree (or equivalent) in molecular/cellular biology/biochemistry, with a solid background and research experience in cancer biology and knowledge of DNA repair or chromatin dynamics
  • Wet laboratory and analytical skills, demonstrated experience in cell culture, as well as in the characterization of nucleic-acids, proteins, IHC, RNAi and bioinformatics will be considered as strong assets,
  • Excellent time management, rigour, perseverance, scientific creativity and originality, writing skills, conciseness, sense of priority and ability to work with others,
  • Language skills: fluent command of English, knowledge of other languages of the European Union is an asset
  • Dr Eric Van Dyck ([email protected])

  • Contract type : 2-year fixed-term contract

  • Work hours : Full time

  • Location : Strassen

  • Start date : ASAP

  • Ref : MC/PHDDRC0823/EVD/DRC


    Applications including a cover letter and a curriculum vitae should be sent through our website via the apply button below. Please apply ONLINE formally through this web page. Applications by email will not be considered. All interested candidates irrespective of age, gender, race, disability, religion or ethnic background are encouraged to apply.


    The LIH is an equal opportunities employer. We are fully committed to removing any discriminatory barrier related to gender, and not only, in recruitment and career progression of our staff.

    The LIH is attentive to gender representation among its leadership staff and aims to eliminate obstacles to the recruitment and promotion of female leaders and their career development.

    From this employer

    Recent blogs

    Recent news